<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8516914A-E800-4912-8655-0000B0B08CAB"><gtr:id>8516914A-E800-4912-8655-0000B0B08CAB</gtr:id><gtr:firstName>Margaret</gtr:firstName><gtr:surname>MacLean</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7A2A3A6C-A99D-4A8C-A176-12F1FDF30534"><gtr:id>7A2A3A6C-A99D-4A8C-A176-12F1FDF30534</gtr:id><gtr:firstName>Yvonne</gtr:firstName><gtr:surname>Dempsie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801171"><gtr:id>DF802E7E-DA7B-495D-B64F-FEF62B488A47</gtr:id><gtr:title>Effect of oestrogen on the serotonin system : role in the development of pulmonary hypertension</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801171</gtr:grantReference><gtr:abstractText>Pulmonary hypertension occurs when the blood vessels of the lung close down. It is a fatal disease with patients dying within 3-5 years of diagnosis. It occurs more in females than males yet the reason for this is unknown. We have identified a possible reason for this. Serotonin is a chemical produced primarily by the gut but also by the lungs. It has a variety of effects including the ability to close down the blood vessels of the lungs. During pulmonary hypertension the activity of the serotonin system is increased. In mice models of pulmonary hypertension where the serotonin system is artificially increased, it is female mice that develop pulmonary hypertension. We wish to investigate if the female hormone oestrogen interacts with serotonin in such a way as to promote the development of pulmonary hypertension.</gtr:abstractText><gtr:technicalSummary>Both idiopathic pulmonary hypertension (PAH) and familial PAH occur more in females than in males. We will test the following hypothesis: ?Serotonergic and oestradiol pathways converge and interact and this underlies gender differences in the development of pulmonary hypertension.? We will study models of PAH in which there is an increased activity of the serotonin system. These are mice that over-expression the serotonin transporter (SERT+ mice) and mice treated with dexfenfluramine (Dfen). Female SERT+ mice develop much greater PAH than male SERT+ mice and male mice do not develop Dfen-induced PAH. Hence SERT+ mice and Dfen ?treated mice will be used to test the hypothesis. We will determine if ovariectomy (Oce) will abolish the PAH phenotype observed in female SERT+ mice before and after exposure to hypoxia. PAH will be assessed by measuring pulmonary pressures and resistance in vivo (under anaesthesia) as well as right ventricular hypertrophy and pulmanary vascular remodelling. We will also investigate if Oce will abolish Dfen-induced PAH in female mice and if Ove affects the expression of elements of the serotonin system in pulmonary arteries (e.g. SERT, receptors, tryptophan hydroxylase). We will investigate if oestrogen will induce a PAH phenotype in male SERT+ mice or male mice treated with Dfen. We will also investigate what genes are differentially regulated by gender, SERT over-expression and Dfen-administration by Affymetrix GeneChip array analysis. Using cultures of pulmonary artery smooth muscle cells (PASMCs) and pulmonary artery fibroblasts (PAFs) we will determine if oestrogen influences the serotonin system (and related signalling pathways). We will examine further the effects that over-expression of SERT, or Dfen administration may have on the ability of E2 to induce proliferation (or enhance serotonin-induced proliferation) in PASMCs and PAFs. This research falls into two current MRC priority areas 1. respiratory medicine ? SERT gene polymorphism determines the severity of PAH in hypoxemic patients with COPD and women have more severe COPD and greater COPD-associated mortality. Hence this research addresses the aetiology of COPD and the biological basis for the observed variation in disease progression. 2. integrative physiology ? this work integrates whole animal research with gene analysis and cellular studies with the aim to help promote understanding of normal function and the physiology of PAH.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-14</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>200000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Social Science event with BHF Scottish Parliament</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AF55F192-5247-419E-B98F-F69587F02458</gtr:id><gtr:impact>We held a science cafe in the Scottish Parliament with BHF Scotland as part of their 'Social Science' event in January 2017.</gtr:impact><gtr:outcomeId>58c1168994f2c5.74863657</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BHF Social Science event SNP party conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>69D33864-DD76-47F3-BFEB-6357DC88DF6F</gtr:id><gtr:impact>Ran a Science Cafe for BHF at their Social Science event at the SNP conference in October 2016</gtr:impact><gtr:outcomeId>58c11c932ee543.33400846</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Society Pairing Scheme</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>539476DC-16A9-4F5F-966F-5C61B1D3DEBA</gtr:id><gtr:impact>As I am a Royal Society Wolfson Fellow I engaged in the Royal Society Pairing Scheme in 2011 and was paired with an MP and spent a week at Westminster.

The MP Ann McKechin spent a day with my research group.</gtr:impact><gtr:outcomeId>q7cQyaC7VnZ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Scientifique</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4CC80EB8-7017-4BBF-BF0C-167C92559470</gtr:id><gtr:impact>I have run Glasgow's Cafe Scientifique since March 2004 and as such all my research comes into play at many levels on a monthly basis. These events are held every month at the Tron Theatre Glasgow.

In 2014 we held a special tenth year birthday event with multiple speakers and 100 members of public attended.

Great public interest and appreciation</gtr:impact><gtr:outcomeId>ECF3D2DB9C6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://tinyurl.com/cafesciglasgow</gtr:url><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>443000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF special project grant</gtr:description><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>SP/12/9/29593</gtr:fundingRef><gtr:id>0323C584-5A12-424B-9FAA-7D1E7F828E16</gtr:id><gtr:outcomeId>RdnkdfGGRsQ</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Scottish Government, Science and Society Division awards</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:id>107DD8BE-3936-4142-8528-AC79650E052D</gtr:id><gtr:outcomeId>bqvHHmCqV9i</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Systems Biology Support</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>F36EE271-F6B1-4109-9436-50AEC46C63CB</gtr:id><gtr:outcomeId>eiYkvEkC7d7</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Capacity Building studentships</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1E5EE3B0-09F9-44C9-A147-C42FA5B215E3</gtr:id><gtr:impact>See 'additional funding'. Through Research Council training competitions, have provided in vivo training opportunities for 19 PhD students and 27 masters students.</gtr:impact><gtr:outcomeId>TbBZDh9ko5T</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Capacity Building in in vivo skills 'Integrative Mammalian Biology'</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>67AB4CDD-C23C-4328-8320-1D132D3D6EA6</gtr:id><gtr:impact>In 2005, 2007 and 2008 ABPI published reports of a shortage in in vivo skills in the UK. We have trained over 260 researchers in in vivo skills building capacity for the pharmaceutical sector.</gtr:impact><gtr:outcomeId>ZayLE3n8uh8</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BBSRC Animals Advisory Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E323BCEA-F85E-447B-8482-4614B79C1B9A</gtr:id><gtr:impact>Participated in discussions on new EU directive on animals in research and also BBSRC policy on use of animals.</gtr:impact><gtr:outcomeId>QwatRpnJSd8</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Acknowledgment of gender differences and novel research models</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2CA46ACF-BC3C-4EAD-81C6-3C88C6D667B6</gtr:id><gtr:outcomeId>c1nJhpbYngk</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Via two BBSRC Follow on Funs with Robert Glen, Cambridge have designed novel 5HT1B antagonists.</gtr:description><gtr:id>572B0E1B-6EF2-446D-990B-C91DBA7C5E88</gtr:id><gtr:impact>Novel 5HT1B antagonists may be used for pulmonary hypertension and angina</gtr:impact><gtr:outcomeId>m46KS196Bv1</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>5HT1B antagonists</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New models of pulmonary hypertension with female susceptibility at an older age.
-The SERT+ mouse
-the Mts1+ mouse
-the Dexfenfluramine-dosed mouse
-the Smad1+/- mouse</gtr:description><gtr:id>83227770-0934-45F4-9F3E-007BE98F1091</gtr:id><gtr:impact>Has refocused research into gender influences and many groups now study older female mice rather than 2month old males.</gtr:impact><gtr:outcomeId>RxLHM6QZngq</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>novel model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6E4A1D72-416D-4A82-A323-CB2DA0153328</gtr:id><gtr:title>The influence of gender on the development of pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Experimental physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95e9c2e463e22500a4e7c0b5606e5faa"><gtr:id>95e9c2e463e22500a4e7c0b5606e5faa</gtr:id><gtr:otherNames>Dempsie Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0958-0670</gtr:issn><gtr:outcomeId>pm_13213_23_23625955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7D29822-C088-4FD6-B085-1D0444D48443</gtr:id><gtr:title>The serotonin transporter, gender, and 17? oestradiol in the development of pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73ffaac9e59ce4ff4c9566ef8432a1d8"><gtr:id>73ffaac9e59ce4ff4c9566ef8432a1d8</gtr:id><gtr:otherNames>White K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>pm_13213_23_21177701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85655A05-1076-440F-93DB-388727F66EEA</gtr:id><gtr:title>The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies.</gtr:title><gtr:parentPublicationTitle>Pulmonary circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29ff820e9688d8ef29d7a20ca0396b0f"><gtr:id>29ff820e9688d8ef29d7a20ca0396b0f</gtr:id><gtr:otherNames>von Gise A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-8932</gtr:issn><gtr:outcomeId>546090198a83b3.27827163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A66B5F2-54B0-40B4-A5B4-01B0A7AF8C4C</gtr:id><gtr:title>The serotonin hypothesis of pulmonary hypertension revisited.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53a6e94ac3c5c7ebd2427170828414ef"><gtr:id>53a6e94ac3c5c7ebd2427170828414ef</gtr:id><gtr:otherNames>Maclean MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>DaGWhzXa9tp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9555D905-B770-4C7F-86CD-AC866465D171</gtr:id><gtr:title>Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH.</gtr:title><gtr:parentPublicationTitle>Physiological genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73ffaac9e59ce4ff4c9566ef8432a1d8"><gtr:id>73ffaac9e59ce4ff4c9566ef8432a1d8</gtr:id><gtr:otherNames>White K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1094-8341</gtr:issn><gtr:outcomeId>pm_13213_23_21303932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>129F7030-ABEB-4639-8E87-B464CA99E94B</gtr:id><gtr:title>Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95e9c2e463e22500a4e7c0b5606e5faa"><gtr:id>95e9c2e463e22500a4e7c0b5606e5faa</gtr:id><gtr:otherNames>Dempsie Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>pm_13213_23_23519266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>220B0B51-747F-4A15-ADC0-38820BAA3F98</gtr:id><gtr:title>Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4c139084ccbf25f1aa6ed9b69f5df80"><gtr:id>a4c139084ccbf25f1aa6ed9b69f5df80</gtr:id><gtr:otherNames>Caruso P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>pm_13213_23_20110569</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801171</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>